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Abstract
Introduction: Lung cancer is the most common cancer in Poland and worldwide, and the leading cause of cancer-related deaths. 
Compared to the present day, the annual number of new cases of lung cancer will have increased by approximately 50%, by 2030. 
The overall ratio of mortality to incidence totals 0.87 and is among the highest. The five-year survival rate in Poland has recently 
achieved 13.4%. In 2015, lung cancer screening using low-dose computed tomography (LDCT) was introduced to routine clinical 
practice in the United States following the publication of the largest randomised study, The National Lung Screening Trial. The 
implementation of screening programmes in Poland and the rest of Europe also seems unavoidable. Due to the differences, both 
in the socioeconomic considerations and healthcare funding, compared to that in the United States, the current approach comes 
down to the awaited results of the European randomised study, NELSON.
Material and methods: During the meeting of an expert panel at the “Torakoneptunalia 2016” conference in Jastarnia, Poland, 
a decision was made to summarise and publish the current data on LDCT lung cancer screening in the form of recommendations, 
or a position statement. The document was prepared by a team composed of a radiologist, thoracic surgeons, pulmonologists, 
clinical oncologists, epidemiologists, internists, health prevention specialists and pathologists. It reflects the current body of 
knowledge about lung cancer, its diagnosis and treatment, and provides recommendations on early detection of lung cancer using 
LDCT. The recommendations address the screening procedure, the requirements for the teams conducting the screening, and the 
requirements for radiologists, pathologists and surgeons involved in the diagnosis and treatment of patients.
Results: While awaiting the results of the NELSON study on lung cancer screening methodology, the multidisciplinary group of experts pre-
sents their position, laying grounds for the development of an action plan for early detection of lung cancer in the upcoming future in Poland.
Conclusions: Primary and secondary prophylaxis are the principal ways to reduce lung cancer mortality. While smoking cessation is a task 
of utmost importance, it must be accompanied by an effective screening programme if the outcome of the disease is to be improved.
Key words: lung cancer screening, early detection, secondary prophylaxis
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1. The epidemiology and treatment of lung cancer 
in the world, Europe and Poland
According to the World Health Organisation 
(WHO), lung cancer is the most common cancer 
in the world (about 1.8 million new cases annu-
ally, accounting for nearly 13% of all new cancer 
cases). Males account for 68% of all patients. Lung 
cancer kills an estimated 1.2 million people each 
year (17% of all cancer deaths) [1]. Approximately 
85–90% of lung cancer deaths are closely associa-
ted with smoking, with non-smokers accounting 
for about 10–15% of all lung cancer patients [2]. 
Several studies investigating lung cancer unrelated 
to smoking have revealed exposure to certain carci-
nogenic factors (occupational exposure to risk fac-
tors, second-hand cigarette smoke, fume pollution 
at household, atmospheric smog). The molecular 
and genetic profile is of critical significance in this 
separate category of lung cancer [3]. 
The incidence of lung cancer shows a conside-
rable regional variation. Due to the high mortality to 
incidence ratio totalling 0.87, mortality data can be 
regarded as an approximate measure of incidence. 
The highest mortality rates in men (about 50 per 
100,000) are reported in the countries of Central and 
Eastern Europe (including Poland) and in Central 
and East Asia. The lowest mortality rates (about 2 
per 100,000) are recorded in the countries of Central 
and West Africa. The pattern of prevalence of lung 
cancer in women is slightly different and also follows 
the distribution model of smoking, with the highest 
mortality rates being observed in North America (34 
per 100,000) and Northern Europe (24 per 100,000), 
slightly lower rates being reported in the countries of 
Central Europe (including Poland) and Asia (below 
20 per 100,000), and the lowest rates being found in 
West Africa and the Middle East (about 1 per 100,000) 
[1]. In Europe, lung cancer was the most common 
cause of cancer mortality in men (254 thousand; 
26%) and also accounted for 13% of cancer deaths in 
women (99 thousand) in 2012. Since the mid-1990s, 
a downward trend has been noted in the incidence 
of lung cancer in most European countries [4]. No 
such favourable trend is, however, observed in wo-
men [5]. In 2013, a 6% relative decrease compared 
to 2009 was noted in lung cancer mortality among 
men in the countries of the European Union, while 
mortality in women increased by 7% during that 
period, approaching the value in men [5–7].
In Poland, 14,600 and 7,000 new cases of lung 
cancer are diagnosed annually in men and in wo-
men, respectively (with age-standardised incidence 
rates of about 48 per 100,000 and 18 per 100,000, 
respectively), which accounts for 19% and 9% of all 
new cancer cases in men and in women, respectively 
[6]. Since 2007, lung cancer has continued to be the 
most common cause of cancer death not only in men 
(31% in 2013) but also in women (16% in 2013) [8].
The main cause of the lung cancer epidemic, 
both worldwide and in Poland, is tobacco smoke. 
This has been proven by many historical studies, 
both on the population [9] and biological [10] level. 
Association between tobacco smoking and risk of 
disease is a cause-effect and dose-response type of 
relation [11]. Reducing a population rate of tobacco 
smoking should be a priority for the healthcare 
system and a moral duty of every physician. Me-
asurable benefits coming from such an approach 
were demonstrated in a  theoretical model [12] 
and in empirical studies, also in Poland [12, 13]. 
The declining trend of lung cancer incidence and 
mortality in Polish men is the result of reduction 
in tobacco smoking. Unfortunately, this beneficial 
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phenomenon has not been observed among women. 
From the population viewpoint, the most effective 
action against lung cancer, is primary prevention 
leading to reduction of smoking prevalence.
Lung cancer is associated with a low survival 
rate, due to its long asymptomatic course that al-
lows it to remain undetected until it is in an advan-
ced stage. In the United States, the 5-year survival 
rate of lung cancer was reported at 17.4% [7]. 
The 5-year survival rates for lung cancer in the 
67 countries participating in the CONCORD-2 
study for the most recent follow-up period (dia-
gnosed in the years 2005–2009) ranged from 2.2% 
in Libya to 16.5% in Switzerland, 18.7% in the 
United States and 30.1% in Japan. In Poland, 
survival has increased from 11.4% to 13.4% [14]. 
2. Detection of lung cancer
The clinical manifestations of lung cancer de-
pend on its clinical stage, histological type, tumour 
location and the presence of distant metastases. In 
some patients, who are clinically asymptomatic, 
lung cancer is diagnosed incidentally on imaging 
during investigation of unrelated problems. 
The most common symptoms of central and 
endobronchial tumours are cough and haemopty-
sis. Further growth of endobronchial tumours may 
lead to atelectasis, which is often accompanied by 
inflammatory or suppurative processes. 
Peripheral tumours may also cause dyspnoea 
due to airway obstruction and symptoms associa-
ted with pleural infiltration such as pain, effusion 
or chest wall destruction. In patients with advan-
ced disease, the most common manifestations inc-
lude general symptoms (asthenia, weight loss, low-
grade fever) and symptoms specific to the location 
of metastases (bone pain). In about 10–20% of the 
patients, the diagnosis of lung cancer is preceded 
by paraneoplastic syndromes (SIADH, carcinoid 
syndrome, Cushing’s syndrome, Lambert-Eaton 
myasthenic syndrome, hypertrophic pulmonary 
osteoarthropathy, hypercalcaemia) [15].
The purpose of the diagnostic evaluation of 
lung cancer is to establish its histological type and 
stage. The principal elements of the diagnostic 
process in lung cancer are medical history, phy-
sical examination, imaging studies and invasive 
diagnostic procedures.
The main imaging modality used to diagnose 
lung cancer is computed tomography of the chest 
[16]. With the advent of low-dose computed tomo-
graphy (LDCT), plain radiography is gradually losing 
its significance, although it is still the most common-
ly ordered investigation in clinical practice in Poland.
The purpose of non-invasive evaluation is to 
detect lung cancer and, if detected, to establish its 
TNM stage. PET-CT is the most valuable imaging 
modality in detecting metastases to mediastinal 
lymph nodes and to distant organs. Imaging is 
also useful in the monitoring of treatment efficacy.
The most common radiological manifesta-
tions of lung cancer include a coin lesion (solitary 
pulmonary nodule), hilar enlargement, atelecta-
sis or emphysema and pleural effusion. PET-CT 
is currently used to detect remote metastases. 
Patients being considered for curative surgery or 
radiotherapy, require an assessment of pulmonary 
function (spirometry, diffusing capacity testing) 
and cardiovascular function (ECG, echocardio-
graphy).
The final diagnosis is established on the basis 
of histopathological or, less frequently, cytolo-
gical examination. Tissue samples for examina-
tion are collected during bronchoscopy, EBUS/ 
/EUS, transthoracic biopsy of peripheral lesions, 
mediastinoscopy or thoracotomy. The resulting 
histopathological specimens are used to deter-
mine the histological type of the tumour (small 
cell lung carcinoma, adenocarcinoma, squamous 
cell carcinoma etc.) and to carry out molecular 
testing (activating mutations in the EGFR gene, 
ALK gene rearrangements etc.), which determines 
further targeted therapy. Cytology is of limited 
diagnostic significance in lung cancer. It can be 
useful for patients in whom tissue samples cannot 
be obtained due to technical reasons or a poor 
performance status.
Positive prognostic and predictive factors inc-
lude the following: early stage of the disease, good 
performance status (Zubrod/ECOG score of 0–1 
or 2), absence of clinically relevant weight deficit 
(a weight loss of no more than 5%), female sex [17]. 
The presence of activating mutations in 
the EGFR gene (exon 19 deletions and exon 21 
mutation) and rearrangements in the ALK and 
ROS1 genes, have been reported to be predictive 
factors in treatment response to tyrosine kinase 
inhibitors (TKIs), but they are not recognised pro-
gnostic factors in survival, whichever treatment 
is used. Mutations in the EGFR gene are found 
in about 10–16% of adenocarcinomas in the Eu-
ropean population and are unrelated to exposure 
to tobacco [18]. 
The presence of rearrangements in the ALK 
gene is associated with specific clinicopathologi-
cal features, namely an earlier age at diagnosis in 
never-smokers and patients with a short history 
of smoking, and the histological type of the ade-
nocarcinoma [19].
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KRAS mutations are found in about 25% of pa-
tients diagnosed with adenocarcinoma of the lung. 
They are associated with smoking and are a negative 
prognostic and predictive factor in TKI treatment [20].
Other biomarkers, such as rearrangements in 
fusion genes, are being actively investigated as 
potential targets for new therapeutic technologies.
3. Screening in the United States,  
Europe and Poland
The aim of population screening program-
mes is to reduce mortality in the general popu-
lation [21] by detecting the disease in its early, 
asymptomatic stage, in order to treat it effecti-
vely and, as a result, to prevent deaths from the 
disease. Activities aimed to prolong survival and 
to improve the quality of life, do not meet the 
definition of a population screening programme. 
However, the increasing possibilities of treat-
ment interventions in patients with early-stage 
lung cancer, which can prolong survival and 
improve the quality of life, have triggered the 
development of screening programmes aimed 
to detect this malignancy in groups particularly 
exposed to risk factors, namely, in this case, to 
long and intensive smoking. The set of activities 
can be considered screening programmes for 
high-risk groups. 
In the case of lung cancer, screening is in-
tended for the asymptomatic subpopulation at 
a given age (over 50–55 years) with a determined 
minimum tobacco exposure (at least 20–30 pack- 
-years, depending on the recommendations). 
These features define the high-risk group basing 
on the demonstrated dose-effect relationship 
between smoking and lung cancer [22]. 
According to some recommendations, ad-
ditional risk factors (passive smoking, exposure 
to radon, environmental and occupational expo-
sure to carcinogens, lung diseases not related to 
cancer, such as chronic obstructive pulmonary 
disease [COPD], idiopathic pulmonary fibrosis 
[IPF], a personal history of lung cancer or lung 
cancer in a first-degree relative) can also be taken 
into account when selecting the target group.
Screening programmes using conventional 
chest radiography conducted between 1950 and 
1970 with or without sputum cytology, failed to 
show any statistically significant reduction in 
lung cancer mortality. This has been confirmed in 
a randomised phase 3 study (The Prostate, Lung, 
Colorectal and Ovarian — PLCO), which showed 
that annual screening assessments using chest ra-
diography were useless in high-risk individuals [23].
Since the 1990s, low-dose computed tomo-
graphy (LDCT) has been used as a screening tool. 
Chest LDCT is a  safe non-contrast diagnostic 
procedure involving 10–30 fold lower radiation 
dose compared to standard CT examination. LDCT 
screening is intended to detect non-calcified nodu-
les that may raise suspicion of lung cancer, depen-
ding primarily on their morphology and size, e.g. 
solid nodules; part-solid nodules; ground-glass 
nodules (GGNs). LDCT has a  lower diagnostic 
value in non-solid nodules than in GGNs.
The thin-section of the reconstruction lay-
er enables the detection of small lesions (high 
sensitivity), both benign and malignant [24, 25]. 
LDCT allows to evaluate other pathological 
lesions in the mediastinum, bronchi, lung pa-
renchyma, blood vessels and upper abdominal 
structures visualised during the study.
Analyses of observational studies conducted 
in Japan, the United States and Germany have 
demonstrated that about 85–93% of stage I lung 
cancers can be detected using LDCT [26].
An international non-randomised study in 
over 31,000 high-risk individuals (I-ELCAP), has 
confirmed LDCT to be an effective tool for the 
detection of early lung cancer, with 85% of the 
cancers being detected in stage I. However, due 
to the short follow-up (40 months) and the low 
proportion of participants followed up for more 
than 5 years (only 20%), the projected 10-year 
survival rate of 92% was associated with a signi-
ficant risk of statistical error [27]. 
The results of the National Lung Cancer Trial 
(NLST), the largest randomised clinical study 
that used LDCT for lung cancer screening versus 
chest radiography, that was published in 2011 and 
included over 53,000 participants, showed a 20% 
relative reduction in lung cancer mortality and a 7% 
relative risk decline in all-cause mortality, in the 
study group. On the basis of these results, the Uni-
ted States Preventive Services Task Force (USPSTF) 
recommends screening in the group at high risk 
of lung cancer, i.e. those over 55 years of age and 
a smoking history of at least 30 pack-years [28].
The results of the NLST have changed cli-
nical practice. Since 2015, the Centres for Medi-
care and Medicaid Services (CMS) in the United 
States have covered the costs of LDCT in groups 
at increased risk of lung cancer. Reservations 
concerning the routine implementation of this 
screening, which have also been expressed by us, 
are mainly related to the high percentage of false 
positive results (positive results in at least one of 
the three rounds in 39.1% of the individuals), low 
cancer detection rate (only 3.5%), overdiagnosis 
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and overtreatment in the screened group.
A prospective randomised clinical study is 
currently under way in Europe (NELSON). It has 
enrolled over 15,000 current or former smokers 
with a smoking history of at least 15 pack-years, 
who undergo annual LDCT examinations [29]. 
While awaiting the publication of the study, Eu-
ropean scientific societies, such as the European 
Society of Radiology (ESR), the European Respi-
ratory Society (ERS) and the European Society of 
Thoracic Surgery (ESTS) recommend screening 
as part of long-term programmes conducted in 
comprehensively equipped, multidisciplinary 
and certified centres [30, 31]. 
Another pilot study, the UK Lung Screening 
(UKLS), has confirmed the possibility of detec-
ting lung cancer while it is still in the potentially 
curable stage [32].
The results of these two European studies 
may serve as proof of the efficacy of lung can-
cer screening using chest LDCT, unequivocally 
demonstrated in the American study, the NLST. 
The Table 1 is presenting characteristics of 
the selected randomised controlled lung cancer 
screening trials. 
Several Polish centres, including Gdansk, 
Szczecin, Warsaw, Poznan and Zabrze, have con-
ducted pilot studies using chest LDCT in high-risk 
individuals. In total, almost 50,000 people were 
examined in the above-mentioned centres. Lung 
cancer was detected in approximately 1% of the 
examined individuals (from 0.86% in Szczecin, 
to 1.05% in Gdańsk). Lung cancer in stage I was 
64 to 70% of detected cancers. The results of the-
se studies have highlighted the scale of tobacco 
smoking in the Polish population, indicated the 
growing awareness of the risk of lung cancer in 
the society and confirmed the efficacy of LDCT 
in detecting pulmonary nodules [39, 40]. 
The decision to join a screening programme 
should be a shared decision made by the physician 
and a patient and should be individually discus-
sed, particularly in patients with comorbidities.
4. Pathways for implementing lung cancer 
screening programmes in Poland and in Europe
No lung cancer screening programmes on 
a mass scale similar to those in the United States 
and China, have been implemented in Poland 
or in Europe. The guidelines on lung cancer 
screening based on LDCT are grounded on the 
assumption that such screening programmes or 
pilot projects will be implemented in Poland in 
the near future. Screening programmes using 
LDCT have been recommended by the following 
documents prepared by European organisations 
and societies: the European Respiratory Society 
(ESR)/European Society of Radiology (ERS) white 
paper on lung cancer screening [30], the position 
statement of Swiss University Hospitals [41], 
the position statement of the European Society 
of Medical Oncology (ESMO) [42], the ESTS 
guidelines [31] and the British Thoracic Society 
guidelines [43]. In 2017, the European Union 
position statement on lung cancer screening has 
been published and recommended implementa-
tion of the low-dose CT screening throughout 
Europe as soon as possible [44]. Many coun-
tries (United Kingdom, Netherlands, Belgium, 
Denmark) are developing lung cancer screening 
programmes adapted to country-specific politi-
cal, economic, epidemiological and cultural 
circumstances. Prepared by a multidisciplinary 
team of experts representing all the special-
ties involved in such programmes and having 
experience in conducting screening program-
mes, the document is intended to serve as 
a foundation for the preparation of a national 
programme for early detection of lung cancer.
In 2016, 269,000 people in Europe, including 
22,000 in Poland, died from lung cancer, with 
late diagnosis being the main reason. The aims 
of the screening are early diagnosis, successful 
treatment and mortality reduction. Implementa-
tion of early lung cancer detection programmes on 
a mass scale is a high-priority task for healthcare 
systems in Europe and in Poland. A total of 4 pilot 
programmes have been conducted in Poland so far. 
All of them were short-term projects with only 1–3 
screening examinations conducted in each partici-
pant. A total of about 50,000 people were screened 
in these programmes in Szczecin, Gdańsk, Poznań 
and Warsaw, with more than 500 cases of lung 
cancer being detected, most often in stage I, i.e. 
the stage in which curative surgery is still possible.
Public healthcare management institutions 
in Europe are awaiting the results of the rando-
mised Dutch-Belgian study, NELSON, to be pu-
blished in by 2019. Pathways for implementing 
the screening programmes within the European 
Community are bound to differ from country 
to country, depending on socioeconomic circu-
mstances. Active steps need to be taken in Poland 
to prepare a cost-effective, high-quality program-
me for early detection of lung cancer. The launch 
of the programme should initially be restricted to 
centres with multidisciplinary teams experienced 
in conducting the types of projects and meeting 
the requirements of most guidelines published 
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by world organisations involved in screening 
programmes. The requirements are detailed in the 
next section. Basing on the experience gained by 
the centres, subsequent teams should be trained 
to conduct screening that provides the highest 
possible effectiveness and the lowest adverse 
effects for the participants.
In European countries, the implementation 
of lung cancer screening programmes will most 
likely be based on the experience gained in other 
screening initiatives implemented in the past 
(breast cancer, colorectal cancer). This means 
that these programmes will be in wholly or partly 
financed from public funding in order to give all 
the social groups of citizens equal access to the 
project [45].
5. Expected outcomes of screening 
implementation 
The main goal of secondary prevention of 
lung cancer is to detect it at an early stage to re-
duce mortality associated with the malignancy. 
The ongoing studies in the United States and pilot 
projects in other countries, are aimed to develop 
a management algorithm leading to a significant 
reduction in side effects and adverse events as-
sociated with LDCT screening.
Observational studies have shown an incre-
ased detection rate in early stages of the disease 
(with about 85% of the detected cancers being 
stage I  cancers), which entails considerably 
improved treatment outcomes in this group of 
patients [22].
In 2015, two American analyses were pu-
blished that retrospectively reviewed data from 
the largest randomised screening programme, 
the NLST, using the Lung Imaging Reporting 
and Data System (Lung-RADS™) criteria [46, 47]. 
Basing on these studies, it was proposed to incre-
ase the threshold size for the pulmonary nodule 
to 6 mm, thus defining a positive result of chest 
LDCT. This change allowed to reduce the rate of 
false positive results from 27.6% to 10.6% in the 
study carried out by McKee et al. [46] and from 
26.6% to 12,8% in the analysis performed by 
Pinsky et al. [47].
In an effort to standardise radiological guide-
lines for chest LDCT and to reduce false positive 
results in lung cancer screening, the American 
College of Radiology (ACR) eventually proposed 
a data classification and reporting system accor-
ding to Lung-RADS™. It resembles other radiolo-
gical classification systems, e.g. BI-RADS (Breast 
Imaging Reporting and Data System) approved 
for breast cancer screening, PI-RADS (Prostate 
Imaging Reporting and Data System) used for the 
diagnosis of prostate cancer or LI-RADS (Liver 
Imaging Reporting and Data System), helpful in 
the diagnosis of hepatocellular cancer.
In practice, there are several protocols defi-
ning the conditions of lung cancer screening and 
algorithms to follow if nodules or other suspected 
pulmonary lesions are detected.
6. Risks and problems associated with the 
implementation of screening programmes
Prognosis in lung cancer strictly depends 
on the initial stage of the disease at diagnosis. 
The 5-year survival rates in non-small cell lung 
carcinoma (NSCLC) are as follows: 49% and 45% 
in stages IA and IB, 30% and 31% in stages IIA 
and IIB, and 14% and 5% in stages IIIA and IIIB, 
respectively. Only about 1% of NSCLC patients 
with stage IV disease survive 5 years after dia-
gnosis [48].
In the NLST, 40% of the lung cancers were 
in stage IA, 12% in stage IIIB and 22% in stage 
IV. The respective proportions in the control arm, 
the chest radiography arm, were 21%, 13% and 
36%. The proportion of lower-stage cancers is 
therefore increasing, as is the proportion of lobec-
tomies versus pnemonectomies (1% in screening 
studies versus 20–30% of pneumonectomies in 
symptomatic patients) [49]. 
The drawbacks of screening in lung cancer 
include the following:
1. Detection of clinically irrelevant lesions, 
among them indolent lung cancers; there 
is still an unmet need for effective tests 
that would assist in differentiating between 
malignant and benign nodule phenotypes 
(molecular screening, immunological evalu-
ation, state-of-the-art techniques in nuclear 
medicine and radiology etc.). 
2. A negative psychosocial repercussion among 
people who do not accept the idea of living 
with a  pulmonary nodule in their bodies 
(where management according to the algo-
rithm guidelines is not required). 
3. The need to use invasive diagnostic methods, 
which expose the patient to potential side 
effects.
4. The risk of unnecessary surgery (surgical 
treatment of non-cancerous nodules). 
5. The risk of delayed treatment of lesions sugge-
stive of a benign nature (management accor-
ding to the algorithm imposing specific time 
intervals during observation of the nodule). 
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6.  Suppression of vigilance in smokers: “since 
there are tests now that can detect lung cancer 
early, I don’t need to quit smoking”. 
7. High costs of detecting one cancer case among 
the screened individuals (about PLN 30,000 
in Poland and much more in Europe and the 
United States). 
LDCT screening identifies both malignant 
and benign non-calcified nodules. While the 
overall proportion of false positive results in 
the study group of the NLST was high (96.4%), 
the cumulative risk of a false positive result was 
33% in individuals undergoing screening in two 
consecutive annual scans. The use of LDCT in 
the NLST was therefore characterised by a high 
sensitivity and a relatively low specificity. The 
use of volumetric analysis for the assessment of 
pulmonary nodules in the NELSON study is likely 
to significantly decrease the proportion of false 
positive results [50]. 
The categorisation and reporting of the 
detected lesions can be inconsistent. There-
fore, there is a  need to rationalise and unify 
the diagnostic algorithms used so far. In an 
effort to reduce the number of false positive 
results in lung cancer screening, the American 
College of Radiology (ACR) proposed a  data 
classification and reporting system according 
to Lung-RADS™ based on approaches adopted 
in other cancers. 
The use of LDCT as a screening tool is asso-
ciated with detecting a relatively high proportion 
of pulmonary nodules in the screened population 
(an average of 20%), most of which will turn out 
to be benign. The additional investigations that 
the volunteers must undergo, increase their expo-
sure to ionising radiation and may also involve 
additional invasive procedures. 
Despite a  relatively low dose of radiation 
used in the screening (approximately 1.5–2 mSv 
per examination), the radiation dose increases 
to 8 mSv and 14 mSv if the lesions identified by 
LDCT require further evaluation by diagnostic 
CT or PET-CT, respectively. On the basis of the 
NLST, it has been estimated that the cumulative 
radiation dose absorbed during 3 years of lung 
cancer screening is about 8 mSv (including both 
screening and diagnostic scans).
The influence of radiation exposure on the 
risk of inducing another carcinoma was exten-
sively studied in lung cancer screening pro-
grammes. Rampinelli et al. [51], analysed the 
results of the COSMOS programme, in which 
over 5,000 people were subjected to low-dose CT 
screening. During the 10 years of the programme 
implementation, over 40,000 LDCT studies and 
over 600 PET-CT examinations were carried out. 
The reported risk of radiation-related cancer 
was approximately 0.05%. Due to the significant 
impact of the LDCT screening on reducing mor-
tality from lung cancer, it was considered as an 
acceptable risk.
In the NLST, the proportion of invasive 
non-surgical procedures in patients with benign 
lesions was high (73%). In terms of unneces-
sary operations, the proportions were 1.2% for 
biopsies and bronchoscopies, and 0.7% for me-
diastinoscopies and thoracoscopies [33]. 
The largest number of overdiagnoses in 
screening programmes has been reported for bre-
ast cancer, prostate cancer and, more recently, for 
lung cancer screening with LDCT. Overdiagnosis 
refers to the detection of subclinical lesions or 
indolent tumours that do not cause symptoms 
and will not decrease the patient’s life expectancy. 
Detection of such lesions may result in unne-
cessary diagnostic procedures and treatments, 
psychological burden associated with patient 
awareness of the disease, and certain economic 
consequences. Overdiagnosis may unjustifiably 
inflate curability and survival statistics. In the 
NLST, the proportion of indolent tumours has 
been estimated at over 18% [52]. 
The effect of LDCT screening on the quality 
of life is unclear. In the NLST and the NELSON 
study, the quality of life assessment was conduc-
ted in patients undergoing the screening. 
Among the participants of the NLST, inc-
luding those with false positive results, no in-
creased rate of anxiety or any differences in the 
quality of life were observed 1 and 6 months after 
the end of the screening [53]. 
In the NELSON study, about 88–99% of the 
screened patients did not report any negative 
effects of the screening, although 46% reported 
distress associated with the wait for the results. 
No differences in the quality of life were, however, 
observed during 2 years [54]. 
It has been suggested that participation in 
a screening programme may provide the parti-
cipants with false reassurance and a reason for 
continuing to smoke. Active smoking cessation 
counselling should be an integral part of any 
screening programme. 
7. Requirements for screening centres:  
the multidisciplinary team
A  Lung Cancer Screening Centre will be 
a centre providing high-quality medical services 
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and must meet the highest quality requirements 
in the implementation and effective conduct of 
recruitment among individuals at high risk of 
lung cancer, in the performance of LDCT scans, 
the correct interpretation of the scans, and the 
provision of standard instructions regarding 
further follow-up or evaluation and effective 
treatment of patients diagnosed with lung cancer. 
The Centre should have specialists in all the 
relevant fields who will work in a multidiscipli-
nary team (MDT) and determine each diagnostic 
and therapeutic step during MDT meetings. The 
Lung Cancer Screening Multidisciplinary Team 
(LCS-MDT) should be composed of a radiologist, 
pathologist, pulmonologist, thoracic surgeon, 
oncologist, nurse and a co-ordinator experienced 
in the diagnosis and treatment of lung cancer 
and in programmes for early detection of lung 
cancer. All the members of the LCS-MDT must 
be specialists in the respective fields and spe-
cialise in the diagnosis, treatment and long-term 
follow-up of nodules identified in screening. 
Their knowledge should be based on the most 
recent standards and publications related to lung 
cancer screening [55]. The LCS-MDT should 
provide the programme participants with the 
model of lung cancer diagnosis and treatment 
commensurate with the adopted standards and 
recommendations cited in the present document. 
In addition to the above, the Centre must main-
tain the appropriate level of provision of infor-
mation to the participants regarding the adopted 
procedures, and the standards related to uniform 
data acquisition and subsequent collection in 
the general access system in accordance with 
the Polish Society of Cardiothoracic Surgeons 
recommendations [56, 57].
A physician specialising in the treatment of 
tobacco dependence should be an integral member 
of the LCS-MDT [58]committees with expertise 
in lung cancer screening were assembled by the 
Thoracic Oncology Network of the American 
College of Chest Physicians (CHEST. A tobacco 
dependence treatment programme will reduce 
lung cancer mortality and significantly affect 
the cost effectiveness of the programme for early 
detection of lung cancer [59, 60]. All the parti-
cipants of the programme should have access to 
a smoking cessation programme, as part of the 
services provided by the public healthcare system. 
Data on smoking and on the results of cessation 
interventions should be collected in the general 
access system and cyclically analysed [61]. 
Each implemented programme for early de-
tection of lung cancer should provide the data on 
the diagnosis and treatment of its participants to 
a central registry. Efforts should be made to col-
lect biological samples from all the participants 
of such programmes, with the view of conducting 
molecular testing with central registration within 
a biobanking network.
8. Radiological requirements for the equipment, 
absorbed dose and nodule evaluation
An effective screening programme requires 
establishment of a qualified multidisciplinary 
team whose radiologists will ensure that the 
radiation doses are kept to the minimum, while 
preserving sufficient quality of the scans to be 
able to assess the size and morphology of any 
focal lesions and categorise the lesions according 
to Lung-RADS and/or volumetry measurements 
recommended by Henschke et al. already in 1999 
[62, 63], then validated and further developed in 
Nelson trial [50] and UKLS trials [32]. 
It is advisable that the radiologist’s work is 
complemented by the use of computer software 
detecting focal lesions in the lungs, measuring 
their sizes and volumes, calculating their volume 
doubling times and comparing their sizes. Conti-
nued education of the staff and site accreditation 
will contribute to an increased effectiveness of 
the screening programmes.
The diagnostic efficacy of chest LDCT, com-
pared to chest radiography, is four-fold higher in 
detecting malignant lesions and about six-fold hi-
gher in identifying stage I lung cancer [64]. LDCT 
is, however, associated with a higher proportion 
of false positive diagnoses requiring invasive 
diagnostic procedures that are performed on the 
basis of LDCT (7% vs 4% of all participants) [65].
The European Society of Radiology (ESR) 
and the European Respiratory Society (ERS) pu-
blished a joint report in 2015 on early detection 
of lung cancer in Europe, while we are still awa-
iting the final results of the largest randomised 
controlled study in Europe, the Dutch-Belgian 
NELSON study (Nederlands-Leuvens Longkanker 
Screenings Onderzoek), in which almost 16,000 
current or former smokers were screened between 
2003 and 2006. The report emphasises that the 
results of the NLST, a study conducted according 
to a very good methodology, cannot be ignored, 
and recommends using LDCT as a screening tool 
in research studies or clinical practice in certified 
multidisciplinary centres [30]. 
There are several reasons for the recom-
mendation for having only dedicated centres 
conduct screening. Radiologists are responsible 
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for ensuring that the radiation dose is kept to the 
minimum, for having a team of qualified members 
with experience in the assessment of low-dose 
scans, for participating in training and for using 
specific radiological assessment criteria.
The most recent guidelines concerning CT 
scanners published by the American College of 
Radiology and the Society of Thoracic Radiology 
(ACR-STR), partially due to their modest require-
ments, recommend the use of spiral scanners with 
at least 16 detector rows and following the “as low 
as reasonably achievable” (ALARA) principle [66]. 
While following the ALARA principle, LDCT 
examinations should be carried out in a way that 
enables radiologists to establish the diagnosis on 
the basis of an acceptable image quality while 
using the lowest possible radiation dose. Recon-
struction algorithms play a significant role in 
reducing the radiation dose. The iterative dose 
reduction system and the use of multiple-row de-
tector technique (with 128 or more detector rows) 
in the latest CT scanners may reduce the effective 
dose to 0.1 mSv [67]. According to ACR-STR, the 
maximum absorbed dose during LDCT should not 
exceed 3 mGy in the standard patient (height 170 
cm, weight 69.75 kg) [66]. The absorbed doses in 
the NLST and the NELSON study ranged from 2.5 
to 6 mGy at the effective doses of 1 mSv in men 
and 1.3 mSv in women [68].
The LDCT examination must include images 
from the lung apices to the costophrenic angle. 
Scans are obtained in deep inspiration without 
administration of intravenous or oral contrast. 
The maximum slice thickness is 2.5 mm with the 
recommended value of 1 mm.
Ready-to-use protocols for CT scanners from 
various manufactures have been prepared and 
are available on the American Association of 
Physicists in Medicine website [69]. 
According to ACR-STR, the radiologist 
involved in screening tests must be experienced 
in analysing low-dose examinations with a do-
cumented evaluation (interpreting) of at least 
300 chest LDCT examinations in the past 36 
months [70]. Image analysis should be perfor-
med on dedicated diagnostic consoles in order 
to detect early lung cancer (nodule) and not to 
miss any significant lesions. Maximum inten-
sity projection (MIP) reconstructions should 
be used for pulmonary nodule detection [71]. 
The examination should be evaluated in the 
pulmonary window scan by scan. The use of 
a standard window for soft tissue is additionally 
recommended to identify any calcifications or 
enlarged lymph nodes, bearing in mind that 
their assessment in a low-dose scan is limited. 
Any additional significant findings should also 
be reported, such as emphysema and other lung 
diseases, atherosclerosis, including the corona-
ry artery calcification (CAC) score, aneurysms, 
osteopenia and other renal, adrenal, hepatic and 
breast pathologies. All the detected nodules 
should be classified into one of the following 
four categories:
• Solid nodules: nodules that completely ob-
scure the lung parenchyma.
• Part-solid nodules: nodules with fragments 
that do not obscure the lung parenchyma.
• Ground-glass nodules (non-solid nodules): no-
dules that do not obscure the lung parenchyma.
• Calcified nodules.
Follow-up scans should be compared with 
baseline scans, and in the first round of the 
screening programme a check for any prior chest 
CT examinations should be undertaken; and if 
such examinations were carried out previously 
and nodules are detected on screening, a compa-
rative analysis of size and volume based on the 
findings is recommended. 
The nodule size is measured in the pulmona-
ry window on images acquired in the transverse 
plane (not on coronal or sagittal reconstructions) 
in various axes. The mean size of the nodule sho-
uld be calculated from the longest and shortest 
dimensions and from indirect measurements. The 
use of computer-assisted detection (CAD) systems 
and volumetric analyses is advised, which assists 
the radiologist in visualising the lesions and 
decreases incongruent differences between the 
observers’ descriptions. In the case of follow-up 
examinations, these systems allow to compare 
nodule volume (volumetric assessment) [72] they 
do not only provide a numerical value but also 
the volume doubling time (VDT). 
In the Dutch-Belgian NELSON study, nodule 
volume was a useful indicator of malignancy: 
nodule volume changes of 25% over 3 months 
suggested potential malignancy. In Europe, vo-
lumetric criteria based on the results of Nelson 
trial are accepted by the majority of radiologists 
involved in screening. Volumetric analysis accor-
ding to these criteria is recommended, both in the 
first and the control LDCTs, in all non-calcified 
nodules suspected of malignancy. 
In the first NELSON protocol, cut-off values 
for positive/negative result were 50 and 500 mm3 
respectively, and in all cases within this range, 
control LDCT was scheduled in the period shor-
ter than 12 months. Retrospective analysis sho-
wed, however, that small nodules of < 100 mm3 
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(< 5 mm in diameter) were associated with a low 
risk of malignancy and control LDCT in these ca-
ses was the same as in the population without any 
nodules [73, 74]. Nodules ≥ 300 mm3 in volume 
(≥ 10 mm in diameter) required further evalu-
ation: a biopsy or PET-CT. In patients with inter-
mediate nodules with volume 100mm3 to 300 mm3 
(5–10 mm), the control was performed after 3 mon-
ths with VDT measurement [73]. In patients with 
VDT of 400–600 days, lung cancer was estimated as 
intermediate and further decisions were discussed 
on MDT. In patients with nodules where VDT was 
> 600 days, very low lung cancer risk was as-
sessed. Any new nodules on control LDCT with 
volume of 30–200 mm3 (4–8 mm in diameter) were 
considered as suspicious and a checkup after 3 
months was performed in these cases. When VDT 
was < 600 days in such a new nodule, diagnostic 
procedures were implemented like in all nodules 
on baseline LDCT > 200 mm3 [74]. 
In solid lung nodules, a radiologist should al-
ways analyse and consider their structure that may 
be for example typical of intraparenchymal lymph 
nodes, lymph nodes located close to interlobar or 
intersegmental planes or additionally, inflammato-
ry nodules where the evaluation should be based 
not only on size measurement but should include 
the analysis of nodule morphology [75, 76]. 
In pure and partsolid GGO (Ground Glass 
Opacity) nodules, the observation should always 
be considered to avoid invasive diagnostic proce-
dures. In the observation of growth, analysis and 
morphology assessment is crucial for malignancy 
risk assessment [75, 76]. In such a nodule the con-
trol is performed every 12 months if any previous 
CT is available. In newly diagnosed GGO lesions 
checkup after 3 months should be performed and 
subsequently after 12 months if malignancy risk is 
< 10%. When the risk is > 10%, invasive diagnosis 
or operation should be considered.
According to the NELSON study, malignant 
tumours detected by LDCT are more frequently loca-
ted in the upper lobes and on the lung periphery [29]. 
The criteria indicating a benign nature of 
a nodule with an acceptable diagnostic effective-
ness are calcifications and fat, while the growth 
of a nodule with a volume doubling time in the 
range of 20–400 days indicates malignancy. Two
-thirds of smokers are diagnosed with nodules, 
95% of which are less than 10 mm in size with 
3% of them being malignant [33]. 
Evaluation of the nodule structure requires 
clinical experience. In addition to volumetric 
assessment, lesions measuring 10 mm or less may 
also be evaluated using the Lung-RADS criteria 
developed by the ACR to standardise the reporting 
of screening LDCT examinations [46].
Category 1 (< 1% risk of malignancy) com-
prises nodules with the following benign features:
— Completely calcified nodules. 
— Nodules with central, concentric or popcorn-
-like calcifications or fat-containing nodules.
Category 2 comprises benign lesions with a low 
risk of malignancy (< 1%):
— Solid nodules with an average diameter of < 6  
mm, or new nodules (appearing on a subsequ-
ent scan) with an average diameter of < 4 mm. 
— Part-solid nodules with an average diameter 
of < 6 mm on the baseline scan.
— Ground-glass nodules with an average diame-
ter of < 20 mm, or ≥ 20 mm if slowly growing 
or stable during the follow-up period.
— Category 3 and 4 nodules if unchanged for at 
least 3 months.
Category 3 comprises probably benign lesions 
with 1–2% risk of malignancy and includes as 
follows:
— Solid nodules with an average diameter of 
≥ 6 mm and < 8 mm, and new solid nodules 
with an average diameter of ≥ 4 mm and < 6 mm.
— Part-solid nodules with an average diameter 
of ≥ 6 mm and a solid component of < 6 mm, 
and new part-solid nodules < 6 mm.
— Ground-glass nodules larger than 20 mm on 
the baseline scan or new.
Category 4 comprises potentially malignant 
nodules and includes three subcategories: 4A, 
4B and 4X.
Category 4A (5–15% risk of malignancy) 
comprises the following:
— Solid nodules with an average diameter of ≥ 8 mm 
and < 15 mm on the baseline scan, and growing 
nodules < 8 mm, and new nodules with an 
average diameter of ≥ 6 mm and < 8 mm. 
— Part-solid nodules with an average diameter 
of ≥ 6 mm and a solid component of ≥ 6 mm 
and < 8 mm, and new or growing part-solid 
nodules with a solid component of < 4 mm.
— Endobronchial nodules.
Category 4B is associated with a risk of ma-
lignancy exceeding 15% and includes as follows:
— Solid nodules with an average diameter of ≥ 15 
mm, and new or growing nodules of ≥ 8 mm.
— Part-solid nodules with a solid component of 
≥ 8 mm, and new or growing nodules with 
a solid component of ≥ 4 mm.
Category 4X is associated with a risk of mali-
gnancy exceeding 15% and comprises category 3 
and 4 nodules with additional features suggestive 
of malignancy, such as: 
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— spiculations, 
— ground-glass nodules with a volume doubling 
time of one year,
— enlarged regional lymph nodes.
Category 1 and 2 nodules should be followed 
up annually by LDCT. Category 3 nodules require 
a follow-up LDCT in 6 months. The recommended 
management of category 4 nodules involves a fol-
low-up LDCT in 3 months, a biopsy or a PET-CT 
of lesions with a solid component of > 8 mm.
When evaluating a nodule using the Lung- 
-RADS criteria, the measurements should be 
performed on lung windows and reported as the 
average diameter rather than the longest diameter 
(similarly to the reporting of cancer lesions using 
the RECIST classification). For nodules visually as-
sessed as round, no additional measurements need 
to be performed. The increase in lesion size should 
also be defined more precisely and nodule growth 
is defined as an increase in size of ≥ 1.5 mm. 
Lung-RADS systematises the assessment 
of nodules identified in LDCT for the purpose 
of early detection of lung cancer. It is currently 
a standard method used for the assessment of pul-
monary nodules in the participants of screening 
programmes in the United States. It can be easily 
implemented in Poland. On the other hand, in 
Europe, after the publication of selected results of 
the NELSON trial, emphasis is placed on volume-
tric assessment, which is a very accurate method 
but only when performed in experienced centres.
9. Population at risk and risk assessment
In February 2015, the LDCT lung cancer 
screening programme was implemented in the 
United States. Out of approximately 8.5 million 
eligible individuals, a total of about 1.5 million 
subjects were included until December 2016 
(personal communication: Dr Christine D. Berg, 
NCI, USA).
Due to methodological and financial reasons 
and a strong association of the malignancy with 
smoking, the programme for the detection of early 
lung cancer does not cover the entire population 
[30, 77], but only the subpopulation of individu-
als at an increased risk of developing the disease, 
defined by specific age and tobacco exposure.
Fundamental to the screening programme in-
tended for the high-risk population is the correct 
selection of the target group, whose characteristics 
will depend on epidemiological data, medical 
circumstances and the level of financial funding.
In the NLST study and in the USPSTF recom-
mendations, inclusion criteria for the screening 
programme were based on the number of pack- 
-years and the age of the enrolled individuals [33]. 
Currently, after re-analysis of the NLST and PLCO 
cohorts, it is recommended to use predictive 
models of individual risk of developing lung 
cancer, which are based on additional risk para-
meters, that allows to target more precisely the 
screening population [30, 47, 74]. The application 
of the models determining probability of tumour 
malignancy in a given person is an additional 
recommended element increasing the number 
of true positive results [31, 43]. Nevertheless, 
determining the target population of lung cancer 
screening programmes remains a complex and 
empirical problem related to the fact that the oc-
currence of lung cancer in a particular person is 
a multidimensional variable, similar to the trajec-
tory of health. The predictive model appropriate 
for the American population not necessarily is 
appropriate for the Polish population because of 
their differentness, heterogeneity and dissimilar 
response to various factors that are determined 
by environmental influence.
Evaluation of the CT scans should be per-
formed according to criteria specifying how the 
size of the pulmonary nodule (SPN) should be 
measured and defining which results should be 
considered positive and which should be tre-
ated as false positive. All these methodological 
considerations translate into the sensitivity and 
specificity of LDCT in detecting early-stage lung 
cancer and determine its cost and other financial 
performance measures [78].
In the past two decades, considerable pro-
gress has been made in the selection methods, 
in the modelling of the risk group screened with 
LDCT and in the interpretation of CT scans. This 
allows the reduction of the number and frequen-
cy of examinations in the programme and limits 
unnecessary diagnostic procedures.
A positive LDCT result is defined as a non-
calcified solitary pulmonary nodule (SPN) having 
a specific diameter or volume. Pulmonary nodu-
les measuring 2 mm in diameter or smaller are 
observed on CT scans in most adult individuals 
[79]. In the NLST, the proportion of positive re-
sults, i.e. all nodules measuring 4 mm or larger, 
was 27% [33]. This is several times higher than 
that in the NELSON study (2.7%), in which the 
nodules were assessed volumetrically [30]. In the 
latter study, however, a broad category of indeter-
minate nodules (50–500 mm3) was distinguished, 
that were not included in the positive results [77], 
and secondly, the mortality reduction data was 
not published.
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A repeat analysis of the I-ELCAP and NLST 
results [47, 80] has shown that the nodule size that 
requires a follow-up LDCT sooner than after one year, 
may be bigger than initially assumed in the NLST.
False positive results account for a conside-
rable proportion of the detected nodules, as only 
1–4% of them are early-stage lung cancers [30, 77]. 
The following methods are used to reduce 
the number of false positive results:
1. Assessment of risk factors: According to the 
National Comprehensive Cancer Network 
(NCCN) standards, risk factors include as 
follows: smoking, exposure to radon, occupa-
tional exposure (e.g. silica, heavy metals, 
soot, asbestos), personal history of cancer 
(e.g. head and neck cancer in the past), lung 
cancer in first-degree relatives, chronic obs-
tructive pulmonary disease (COPD), idiopa-
thic pulmonary fibrosis (IPF) [81].
2.  If one additional risk factor is present, the 
parameters of the target group are lowered 
from age 55 years and tobacco exposure of 
≥ 30 pack-years, to age 50 years and tobacco 
exposure of ≥ 20 pack-years [81].
3. Use of prediction models: With the use of 
linear regression equations that include the 
above elements and socioeconomic data, it 
is possible to estimate the individual risk of 
developing lung cancer resulting from the 
characteristics of the population of concern 
[81, 82]. Only three of many prediction mo-
dels have provided a more accurate selection 
of individuals for screening, compared to the 
criteria used in the NLST [83]. Furthermore, 
models that take into account the patient’s cli-
nical details and the morphological features 
of the nodule, can determine the degree of 
probability of the nodule being malignant 
[76]. Both classes of the prediction models are 
a great help in individual qualification of sub-
jects for inclusion in a screening programme 
(shared decision-making), particularly when 
discussing the benefits and side effects of the 
programme procedures being planned.
4. Advanced image analysis: radiomics, i.e. the 
evaluation not only of the morphological (se-
mantic) but also the indescribable (agnostic) 
parameters, which better characterise the 
imaged tissue [84].
5. Determination of genomic or protein biomar-
kers obtained from the serum, which confirm 
(positive predictive value) or, in a certain 
configuration, exclude (negative predictive 
value) the presence of cancer in the screened 
patient [85–87].
According to epidemiological data, only 10% 
of lung cancers occur before the age of 55, while 
56% of the cases are found in the 55–74 age group 
[88]. The remaining 32% are found in patients 
aged 75 or older.
Determination of the target population is of 
key importance for the cost effectiveness of the 
screening programme and the desired improve-
ment in the detectability of early lung cancers [89].
The scenario defined as A-55-80-30-15 (whe-
re the letter A  signifies annual screening, the 
numbers “55” and “80” signify the age of starting 
and ending the screening, respectively, the num-
ber “30” refers to tobacco exposure expressed in 
pack-years, and the number “15” indicates the 
longest period since smoking cessation) has pro-
ved optimal in terms of the balance between the 
costs (largely the costs of LDCT scans and medical 
consultations) and the number of lung cancers 
detected and the number of adverse events that 
occurred as a result of diagnostic and surgical pro-
cedures [90]. The tested prediction models were 
calibrated on the basis of the NLST and PLCO 
study results. The above scenario was optimal 
compared to the 120 scenarios characterised by 
the variables described above whose values were 
modified. LDCT performed every 3 years, every 2 
years and every year was shown to reduce lung 
cancer mortality by an average of 6%, almost 10% 
and about 20%, respectively. In a given scenario, 
the number of follow-up LDCT examinations and 
the number of false positive results increases with 
the number of baseline examinations. For exam-
ple, a reduction in the number of pack-years to 
20 and an increase in the duration of the period 
since smoking cessation to 25 years (the A-55-
80-20-25 scenario) results in a 58% increase in 
the number of LDCT examinations and a 26% 
increase in the number of new cases detected. 
The number of LDCT examinations needed to 
prevent 1 death of lung cancer increased from 
550 to 685 cases (24%). Among all the effective 
scenarios, the annual LDCT in patients aged 55 
to 80 shows a marked benefit while preserving 
a moderate level of side effects [90]. The results 
of the analyses and simulations related to the mo-
delling of the population that benefits the most 
from the lung cancer screening programme using 
LDCT, have been taken into consideration to the 
greatest extent in the NCCN recommendations.
The recommendations for inclusion based on 
the stratification of lung cancer risk are as follows:
1. Individuals aged 55 to 74 with tobacco expo-
sure of at least 20 pack-years and the non-
smoking period of no more than 15 years.
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2. Individuals aged 50 to 74 with tobacco expo-
sure of at least 20 pack-years, the non-smo-
king period of no more than 15 years with 
one of the following risk factors:
— Occupational exposure to silica, beryl-
lium, nickel, chromium, cadmium, asbe-
stos, arsenic compounds, diesel engine 
fumes, coal combustion fumes, and soot.
— Exposure to radon.
— Personal history of cancer: lung cancer 
survivor, a history of lymphoma, head 
and neck cancer or smoking-related can-
cers, e.g. bladder cancer.
— Family history of lung cancer in a first-de-
gree relative.
— History of lung diseases: chronic obs-
tructive pulmonary disease (COPD) or 
idiopathic pulmonary fibrosis (IPF).
  A high-risk individual is included in the 
programme based on a shared decision made 
by the subject and their healthcare provider 
(shared decision-making), who discusses with 
the individual the principles of the screening 
programme, the benefits and the side effects 
of the method based on the following:
— The prediction model by Tammemägi: the 
lung cancer calculator PLCOm2012. 
— The prediction model for the malignant 
features of a nodule (McWilliams (Pan-
Can) model) [76].
— Information materials similar to those 
offered by the Agency for Healthcare and 
Research Quality (AHQR) [91].
  The interpretation of LDCT findings 
(the definition of the positive result) and 
further recommendations are in line with 
the Lung-RADS included in the screening 
recommendations NCCN v.1.2017 (see the 
next paragraph).
3. Definition of the false positive result: a solitary 
pulmonary nodule that requires LDCT and/or 
diagnostic and surgical procedures within less 
than one year, and is not an early lung cancer.
4. An individual who meets the programme 
inclusion conditions may become its partici-
pant if they give consent to undergo invasive 
diagnostic procedures and, possibly, surgery.
5. An individual included in the programme 
remains its participant as long as they remain 
a candidate for treatment with a curative intent. 
The A-55-80-30-15 screening scenario tur-
ned out to be optimal for economic and medical 
reasons, i.e. indicated the group in which the 
allocation of funds in the NLST and PLCO cohorts 
were the most effective [90]. Taking into account 
the over-normative air pollution in Poland and epi-
demiological data [8], the team of experts proposes 
the initial scenario A-55-74-20-15, with a reduc-
tion of age in the case of an additional risk factor in 
accordance to the NCCN recommendations. Then, 
the screening scenario of the target population ta-
kes the form of A-50-74-20-15. Cautious estimates 
indicate that the number of people who meet the 
inclusion criteria for screening amounts to around 
2 million in Poland. Assuming that the cost of 
LDCT examination with a radiological report and 
a medical appointment is PLN 300, the estimated 
cost of the examination of the entire population 
with increased risk would exceed PLN 600 million. 
Annually, about 21 thousand persons is de-
veloping lung cancer [8], of which only 17% is 
undergoing surgical treatment, i.e. in an early (lo-
cal or loco-regional) stage (Polish National Lung 
Cancer Registry). Lung cancer screening program-
mes would most likely increase the percentage 
of surgically treated cases [27, 28, 30], which are 
more cost-effective. In the near future, a financial 
amount can be expected to allow screening 3-5% 
of the target population.
10. Smoking cessation programme 
From the participant’s point of view, lung 
cancer screening is often the first significant 
intervention that prompts reflection on how 
smoking affects health. Participants of the 
screening programme receive a lot of informa-
tion and signals whose perception and psycho-
logical effects on behaviour and decisions have 
not been fully studied [92]. 
The risk that lung cancer screening may be 
treated by its participants as an alternative to 
smoking cessation to reduce mortality, has been 
recognised and confirmed by many authors [93]. 
Social determinants of tobacco dependence 
come down to the wider propagation among in-
dividuals with lower economic status, education 
level or social rank. As a result, both the aware-
ness of the harmful effects of smoking and of the 
possibility to receive support is lower than that 
among the middle class representatives [94]. 
The costs of adding a cessation intervention 
to an LDCT lung cancer screening programme 
increase the total cost by a few to over a dozen 
percent. At the same time, the cost effectiveness 
as measured by quality-adjusted life years gained 
increases 1.7- to 5.4-fold [95].
It is therefore beyond any doubt that com-
bining screening with cessation intervention is 
justified. There is still the problem of designing 
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the entire intervention in a way to ensure that the 
percentage of sustained quitters is significantly 
lower and the relapses are less frequent compared 
to spontaneous smoking cessation, because the 
analysis of practical interventions reveals that 
this is not always possible to achieve [96].
It is also advisable to consider the assessment 
of lung age conducted in all the participants, gi-
ven the linear relationship between the lifetime 
number of cigarettes smoked and pulmonary 
function, and the strong correlation of lung cancer 
and COPD [97, 98], and to more actively recruit 
individuals from economically and/or socially 
disadvantaged groups to undergo screening.
We propose the following pathway for 
smoking cessation intervention as part of the 
screening programme:
I. Allocation to specific intervention paths.
Patients being considered for LDCT screening 
are allocated to one of the following three groups on 
the basis of their declarations: active smokers, for-
mer smokers-abstinent for less than 12 months, and 
former smokers-abstinent for more than 12 months. 
By joining the LDCT screening programme, the 
participants agree to the cessation intervention.
II. Active smokers during the screening pro-
gramme undergo the following diagnostic 
evaluations:
— A standardised interview to assess smoking 
intensity and the severity of dependence 
(Fagerström). 
— A test of motivation for smoking cessation 
(Schneider). 
— Measurement of exhaled carbon monoxide 
(Smokerlyzer) or salivary cotinine.
— An assessment of depression (Beck’s scale).
On the basis of the above evaluations, pa-
tients are provided with appropriate support in 
the form of consultation, psychotherapy sessions 
and education. Pharmacological support includes 
nicotine replacement therapy as the first-choice 
treatment, and cytisine, varenicline and bupro-
pion if previous treatment failed or if the patient 
has absolute or relative contraindications to ni-
cotine-containing products. Patients with a positi-
ve evaluation of depression are advised to register 
at an outpatient psychiatric facility.
III. Patients declaring abstinence from smoking 
for less than 12 months undergo Smokerlyzer 
testing (or cotinine testing, if Smokerlyzer 
testing is not possible) and if their non-
smoking status is confirmed, they take a test 
measuring their motivation to continue not 
to smoke and undergo a short intervention 
reinforcing their decision to quit smoking.
IV. Patients declaring abstinence from smoking 
for more than 12 months receive a consulta-
tion to reinforce their motivation to maintain 
the non-smoking status. 
V. All the individuals being considered for the 
screening programme are asked about the 
exposure to passive smoke in their workplace 
or at home. If such exposure is identified, an 
invitation is extended via the patient to the 
patient’s relatives and co-workers to partici-
pate in the cessation intervention. 
11. Evaluation and treatment of lesions detected 
on screening examinations 
One of the most important topics related to 
the conduct of programmes for early detection of 
lung cancer using LDCT is the implementation 
of a detailed algorithm for the diagnosis and tre-
atment of the detected nodules, as most of these 
nodules are benign [55]. The risk of overlooking 
early lung cancer must be minimised, while 
meeting the criteria for high specificity of the 
management in order to limit the unnecessary 
invasive diagnostic and therapeutic interventions 
[39, 99]. It is very important in this context to 
use the new pathological classification system for 
adenocarcinomas and its correlation with the ra-
diological appearance of the nodules [100, 101].
The size of the nodule and its characteristics 
play a significant role in deciding the further course 
of action and determines whether the individual 
will undergo observation, invasive diagnostic 
evaluation or treatment [101]. One-dimensional 
measurement of the nodule diameter is recommen-
ded. Data on the use of volume measurement and 
the volume doubling time (VDT) are very promising 
but require further evaluation [50, 102]. Adoption 
of the lower value of the diameter is of fundamental 
significance for the sensitivity of screening, and 
hence the proportion of false positive results [103]. 
There is currently no commonly accepted 
testing protocol related to a procedural algorithm 
in all the guidelines. We propose to follow the 
Fleischner Society guidelines, adopted by the Na-
tional Cancer Comprehensive Network for studies 
of early detection of lung cancer [81, 104, 105]. 
Nodules detected on LDCT require further evalu-
ation based on the category they are assigned to 
by the radiologist: solid, part-solid or non-solid. 
According to the National Comprehensive Cancer 
Network guidelines, nodule assignment should 
be based on the analysis of the radiological ima-
ge according to the guidelines of the American 
College of Radiology Lung (RADS) [46, 106]. The 
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management in each of the category is based on 
the nodule size.
Solid nodules
Nodules < 6 mm (Lung-RADS category 2, 
probability of lung cancer < 1%) require a repeat 
LDCT after 12 months until the risk of malignancy 
is excluded. 
Nodules 6–7 mm (Lung-RADS category 3, 
probability of lung cancer 1–2%) require a repeat 
LDCT after 6 months.
Nodules 8 to 14 mm (Lung-RADS category 
4A, probability of lung cancer 5–15%) require 
a repeat LDCT after 3 months or consideration 
of PET-CT, which is one of the many diagnostic 
methods available for lung cancer detection. 
The sensitivity of PET-CT for nodules < 8 mm is 
insufficient to consider this modality a  routine 
diagnostic procedure [102].
Nodules ≥ 15 mm (Lung-RADS category 4B, 
probability of lung cancer > 15%) require chest 
CT with contrast and/or PET-CT.
Endobronchial nodules require a  repeat 
LDCT after 1 month or directly after an episode 
of acute cough. In the case of equivocal findings, 
flexible bronchoscopy should be performed.
Patients who have undergone PET-CT should 
be managed as follows:
Where there is low suspicion of lung cancer, 
LDCT after 3 months is recommended.
Where there is high suspicion of lung cancer, 
a fine-needle biopsy is recommended with aspira-
tion of an adequate amount of material for histo-
logical and molecular examination [102, 104], or 
surgical resection of the nodule. Where the biopsy 
rules out malignancy, the patient should undergo 
LDCT after 12 months of observation.
Part-solid nodules
Nodules < 6 mm (Lung-RADS category 2, proba-
bility of lung cancer < 1%) require a repeat LDCT after 
12 months until the risk of malignancy is excluded. 
Nodules ≥ 6 mm with solid component < 6 
mm (Lung-RADS category 3, probability of lung 
cancer 1–2%) require a repeat LDCT after 6 months.
Nodules ≥6 mm or with solid component 
6–7 mm (Lung-RADS category 4A, probability of 
lung cancer 5–15%) require a repeat LDCT after 
3 months or consideration of PET-CT. 
Nodules with solid component ≥ 8 mm 
(Lung-RADS category 4B, probability of lung 
cancer > 15%) require chest CT with contrast 
and/or PET-CT.
Patients who have undergone PET-CT should 
be managed as follows:
Where there is low suspicion of lung cancer, 
LDCT after 3 months is recommended.
Where there is high suspicion of lung cancer, 
a fine-needle biopsy is recommended with aspira-
tion of an adequate amount of material for histo-
logical and molecular examination [102, 104], or 
surgical resection of the nodule. Where the biopsy 
rules out malignancy, the patient should undergo 
LDCT after 12 months of observation.
Non-solid nodules
Nodules < 20 mm require observation and 
LDCT after 12 months until the risk of malignancy 
is excluded. 
Nodules > 20 mm require a  repeat LDCT 
after 6 months.
For solid, part-solid and non-solid nodules, 
appropriate management protocols are used in 
the follow-up of the detected lesions.
Treatment of early lung cancer detected on 
screening follows the guidelines on the treatment 
of lung cancer adopted by the Polish Oncology 
Union. Selected aspects related to non-solid 
nodules are discussed in the section on the re-
commendations for surgical treatment. 
12. Pathology 
Lung cancers include a group of non-small-
cell lung carcinomas, which account for about 
85% of all primary lung cancers, with the rema-
ining 15% being small-cell lung carcinomas [107]. 
Among the histologic types of non-small-cell lung 
carcinoma, adenocarcinoma is the most common 
(approx. 43.2%), followed by squamous cell car-
cinoma (approx. 22.8%) [108].
The WHO Classification of Tumours of the 
Lung, Pleura, Thymus and Heart published in 
2015 introduces the principles of lung cancer 
diagnosis using small biopsies and cytology and 
proposes a new classification of adenocarcinoma 
[109]. The term bronchioloalveolar carcinoma 
(BAC) has been replaced by the following ter-
minology:
• adenocarcinoma in situ (AIS),
• minimally invasive adenocarcinoma (MIA),
• invasive adenocarcinoma [109, 110].
Adenocarcinoma in situ and minimally inva-
sive adenocarcinoma usually refer to a solitary 
lesion or, less frequently, to multifocal lesions 
measuring ≤ 3 cm in diameter characterised by 
the lepidic pattern on microscopic examination. 
In AIS, no stromal or pleural invasion and 
no tumour cell emboli in blood and lymphatic 
vessels are observed, while MIA is characterised 
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by the presence of small foci of invasion ≤ 0.5 cm 
in diameter in a single field. Invasion is defined 
as the presence of a non-lepidic growth pattern, 
most commonly papillary, micropapillary, acinar, 
solid or mucinous, and the appearance of foci of 
stromal invasion [109, 110].
Both lesions are most commonly non-muci-
nous adenocarcinomas, and mucinous AIS and 
MIS are extremely rare. 
On chest CT, both non-mucinous AIS and 
MIA appear as ground glass nodules (GGN) [110]. 
The diagnosis of AIS and MIA is not possible on 
the basis of tissue biopsy or cytology, and requires 
microscopic evaluation of an entire surgically 
resected lesion. Needle biopsy or intraoperative 
examination of GGN to establish the diagnosis are 
not recommended. Both types of lesion carry a very 
favourable prognosis, with 100% of the patients 
surviving 5 years after radical surgery [109, 110].
The most recent, eighth edition of the TNM 
classification of lung cancer (2016) introduced 
a new principle of pathological evaluation of 
tumour size (pT) for tumours with part-solid ap-
pearance on CT (part-solid non-mucinous adeno-
carcinoma). Apart from total tumour diameter, it 
is now essential to determine the size of the solid 
component of the tumour, which corresponds to 
the actual invasive component. Reporting the 
both sizes is therefore recommended, although 
only the pT category is affected by the invasive 
component [111].
Invasive adenocarcinoma is defined as 
a  tumour with morphological structures sugge-
stive of glandular pattern of differentiation on 
standard (H&E) microscopic examination (tu-
bular, papillary or micropapillary structures) or 
with mucin in the tumour cells on histochemical 
examination, or with the expression of immunohi-
stochemical markers of glandular differentiation 
(TTF-1, napsin A, CK7) [109]. Adenocarcinomas 
are an extremely heterogeneous group of tumours 
in terms of morphology and genetics [112, 113]. 
The number of mutations identified in lung ade-
nocarcinomas are very large, and new mutations 
are constantly being discovered. However, targe-
ted therapies are only available for some of them. 
The most common mutations are EGFR, KRAS, 
BRAF and NRAF mutations and ALK, ROS1 and 
MET rearrangements [109, 114, 115]. The morpho-
logy of adenocarcinoma does not only indicate its 
degree of differentiation but also allows to predict 
the possibility of mutations, mainly EGFR, ALK 
and KRAS mutations [113, 115, 116].
Lepidic carcinomas are well-differentiated 
tumours with favourable prognosis and often 
show EGFR mutations. EGFR mutations are often 
seen in acinar, papillary and micropapillary 
carcinomas. Solid tumours with a component 
of signet ring differentiation and acinar tumours 
with cribriform structures may show ALK rearran-
gements, while mucinous tumours may display 
KRAS mutations [113, 116]. In view of the above, 
the histopathological diagnosis of invasive ade-
nocarcinoma of the lung requires specification 
of the predominant morphological pattern and 
the proportions of the remaining microscopic 
components, especially those that indicate a more 
aggressive course of the disease (solid and micro-
papillary components) [109].
13. Additional programmes accompanying lung 
cancer screening 
In 2010, the WHO published guidelines on 
cancer screening methodology. The document 
stated that the four most common causes of death 
in the modern world are cardiovascular disease, 
diabetes mellitus, chronic obstructive pulmonary 
disease (COPD) and cancer. All these conditions 
have the same risk factors and, given the fact that 
all four are preventable, it is recommended that, 
if possible, screening covering all these illnesses 
should be provided together [117]. Low-dose com-
puted tomography offers the possibility to assess 
the severity of coronary artery calcification on the 
scan images, i.e. the CAC score, and the severity of 
emphysema using a dedicated software. Performing 
spirometry in the participants of the screening pro-
gramme will enable the diagnosis of COPD.
The assessment of the coronary artery cal-
cium (CAC) score or the severity of coronary 
artery calcification is feasible on LDCT, and has 
been demonstrated to be non-inferior to contrast
-enhanced CT with ECG gating in assessing the 
risk of death and coronary events. The presence 
of calcifications directly points to the presence 
of subclinical coronary artery disease in the 
individual, and the intensity of calcifications 
corresponds to the severity of the process. The 
CAC score assessment was included in the ACC/
AHA guidelines in 2010, and in the European 
Society of Cardiology guidelines in 2012, as Class 
IIa recommendation (designation as a useful and 
valuable method). The CAC score can easily be 
assessed and measured in each LDCT performed 
in screening programmes, which is currently re-
commended in countries where such programmes 
are in place. The CAC score is considered a valu-
able cardiovascular risk marker in asymptomatic 
adults over the age of 40 [118–120].
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Emphysema and COPD are known positive 
predictors of lung cancer risk, affecting not only 
lung cancer incidence but also all-cause mortality. 
Epidemiological studies, including lung cancer 
screening programmes, have demonstrated a 2- 
to 4-fold increase in new cases of lung cancer 
in patients with COPD compared to healthy 
individuals. This risk is partially due to emphy-
sema susceptible for qualitative or semi-quan-
titative evaluation on LDCT scans. Emphysema 
is a stand-alone risk factor of lung cancer also 
in non-smokers. Risk scales have been develo-
ped for COPD patients to identify individuals 
at an increased risk of developing lung cancer, 
which considerably increases the effectiveness of 
screening programmes, while reducing the side 
effects. Patients with COPD should be included in 
lung cancer screening programmes. Additionally, 
the detection of COPD in patients unaware of 
having this condition, will allow them to receive 
the preventive and therapeutic intervention in 
the form of a smoking cessation programme and 
appropriate treatment [121].
The additional performance of simple and 
inexpensive tests in the participants of the lung 
cancer screening programme, such as a standar-
dised measurement of blood pressure, cholesterol 
and HbA1c (glycated haemoglobin), will allow the 
detection of undiagnosed conditions in a  large 
proportion of these individuals, and in order to 
provide them with appropriate treatment, adjust 
treatment in those inadequately managed.
14. Quality evaluation and training/education. 
Registration and certification of the centres 
A Centre for Early Lung Cancer Detection 
Studies (CELCDS) should be a centre that meets 
the quality requirements specified in the opera-
ting guidelines prepared by Scientific Societies 
and/or by the Ministry of Health published in the 
future as the official announcement. The CELCDS 
should operate in centres with a high level of 
competency and be closely associated with the 
strategy for the diagnosis and treatment of lung 
cancer prepared by the Ministry of Health. 
A. The activities of the centres are subject to total 
quality management (TQM) with the use of 
effectiveness (quality) indicators specified by 
Scientific Societies and/or the Minister of Health. 
B. For the purposes of the reporting and mo-
nitoring of the diagnostic and therapeutic 
processes and their outcomes, the Screening 
Registry is created to include all the evalu-
ated and treated patients. 
C. The CELCDS follows the operating guide-
lines (published in the future as the official 
announcement of the Minister of Health), 
which are subject to monitoring and quality 
assessment (peer review, benchmark etc.). 
D. The CELCDS reports the completed activities 
and the key results of the studies, which is 
necessary for reconciliation of the services 
and for monitoring of the quality and effecti-
veness, and for research purposes. The Lung 
Cancer Registry is created from the reported 
data.
E. Early lung cancer detection studies are sub-
ject to a pilot study (e.g. 3 to 5 centres), 
which will allow the detailed conditions for 
commissioning these centres on the national 
scale, to be defined. 
F. The CELCDS reports the completed activities 
and the key results of the studies, which 
is necessary for reconciliation of the servi-
ces and for monitoring of the quality and 
effectiveness, and for research purposes. 
The Screening Registry is created from the 
reported data.
G. New CELCDS was created basing on training 
at the existing centres of competence iden-
tified in the pilot programme after obtaining 
accreditation from the Ministry of Health.
15. Involvement of thoracic surgeons in 
preparation of screening programmes
Surgeons should be engaged in the screening 
programme and play an important role in its pre-
paration and implementation. Thoracic surgeons 
perform a major function within the multidiscipli-
nary tumour board and his/her decisions must be in 
conformity with current recommendations concer-
ning diagnosis and treatment of early non-small cell 
lung cancer detected in the screening. The main 
goal is to participate actively in the diagnostic wor-
kup and decision making to eliminate or minimise 
surgery for benign conditions. The extent of surgery 
for benign lesions during CT screening should be 
monitored and reported as an indication of surgical 
quality. Moreover, important surgeons’ tasks in the 
screening team are the following: optimission of the 
management of screen detected nodule, reduction 
of false positive rates of surgical biopsies and dec-
line of surgery related trauma.
A  thoracic surgeon participating in the 
screening programme, should fulfil the require-
ments and qualifications described in the „Re-
commendations from the European Society of 
Thoracic Surgeons (ESTS) regarding computed 
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tomography screening for lung cancer in Europe” 
prepared and published in European Journal of 
Cardio-Thoracic Surgery by the group of ESTS 
experts [31]. We recommend to strictly follow 
these recommendations in the preparation and 
implementation of lung cancer screening pro-
gramme in appointed centres.
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